Fintel reports that on February 3, 2025, Redburn Atlantic upgraded their outlook for DexCom (NasdaqGS:DXCM) from Neutral to ...

DexCom (NASDAQ:DXCM) shares received an optimistic update from Redburn-Atlantic, with analyst Issie Kirby (NYSE:KEX) upgrading the stock from Neutral to Buy and increasing the price target to $115 ...

DXCM's top line reflects strong demand for its CGM sensors. International expansion is also driving sales higher. Gross margin reflects inventory damage.

DexCom (NASDAQ:DXCM) shares popped 6% premarket on Monday after the company set its financial forecast for 2025, projecting adjusted gross profit margin of around 64% – 65% on revenue of $4.60B ...

The bull market of the past year or more has reinvigorated investors' interest across a range of industries, and the ...

Medical device specialist DexCom (NASDAQ: DXCM) has substantially underperformed the market over the trailing-12-month period ...

DexCom, Inc. DXCM is well-poised for growth in ... company’s shares have lost 31.2% in the past six months against the industry’s 0.6% growth. The S&P 500 Index has jumped 3.8% in the same ...

sending the medical device maker's shares up nearly 6% premarket. Dexcom's shares had fallen nearly 37% last year, largely due to a slump in July after the company slashed its annual revenue ...

Geneos Wealth Management Inc. lessened its position in shares of DexCom, Inc. (NASDAQ:DXCM – Free Report) by 2.6% in the ...

That marks an 11% increase over 2023. For 2025, Dexcom anticipates total revenue of $4.6 billion, representing expected growth of 14% over 2024. That outlook reflects sensor volume growth driven by ...